The therapeutic potential of anti-CD20: What do B-cells do?

Clinical Immunology

Volumn 117, Issue 3, 2005, Pages 207-213

  Eisenberg, Robert ^a   Looney, R John ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

B cells; CD20; Rituximab

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RITUXIMAB; STEROID;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; CHILL; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; FEVER; HUMAN; HYPOXIA; IMMUNOTHERAPY; INFECTION COMPLICATION; LYMPHOCYTE FUNCTION; MYOSITIS; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SHOCK; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR LYSIS SYNDROME; VASCULITIS; WEAKNESS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS;

EID: 29344460633     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2005.08.006     Document Type: Review

References (101)

1. J. Boye, T. Elter, and A. Engert An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab Ann. Oncol. 14 4 2003 520 535
2. R. Eisenberg SLE-Rituximab in lupus Arthritis Res. Ther. 5 4 2003 157 159
3. G.J. Silverman, and S. Weisman Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy Arthritis Rheum. 48 6 2003 1484 1492
4. C. Kneitz, M. Wilhelm, and H.P. Tony Effective B cell depletion with rituximab in the treatment of autoimmune diseases Immunobiology 206 5 2002 519 527
5. R.J. Looney Treating human autoimmune disease by depleting B cells Ann. Rheum. Dis. 61 10 2002 863 866 (comment)
6. T.S. Lin, M.S. Lucas, and J.C. Byrd Rituximab in B-cell chronic lymphocytic leukemia Semin. Oncol. 30 4 2003 483 492
7. R.J. Looney B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis Rheumatology (Oxford) 44 Suppl. 2 2005 ii13 ii17
8. E. Keystone B cell targeted therapies Arthritis Res. Ther. 7 Suppl. 3 2005 S13 S18
9. M.S. Cragg The biology of CD20 and its potential as a target for mAb therapy Curr. Dir. Autoimmun 8 2005 140 174
10. S.A. Chambers, and D. Isenberg Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases Lupus 14 3 2005 210 214
11. A. Bosly Role of anti-CD20 monoclonal antibody in association with immunomodulatory agents Pathol. Biol. (Paris) 52 1 2004 39 42
12. G.L. Plosker, and D.P. Figgitt Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia Drugs 63 8 2003 803 843
13. W. Rastetter, A. Molina, and C.A. White Rituximab: expanding role in therapy for lymphomas and autoimmune diseases Annu. Rev. Med. 55 2004 477 503
14. D.A. Einfeld Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains EMBO J. 7 3 1988 711 717
15. T.F. Tedder Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes Proc. Natl. Acad. Sci. U. S. A. 85 1 1988 208 212
16. M.J. Polyak, and J.P. Deans Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure Blood 99 9 2002 3256 3262
17. M.A. Valentine Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C J. Biol. Chem. 264 19 1989 11282 11287
18. J.K. Bubien Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes J. Cell Biol. 121 5 1993 1121 1132
19. E.M. Genot Phosphorylation of CD20 in cells from a hairy cell leukemia cell line. Evidence for involvement of calcium/calmodulin-dependent protein kinase II J. Immunol. 151 1 1993 71 82
20. M.P. Cancro B cell maturation and selection at the marrow-periphery interface Immunol. Res. 17 1-2 1998 3 11
21. H. Harada Phenotypic difference of normal plasma cells from mature myeloma cells Blood 81 10 1993 2658 2663
22. S.P. Treon CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications J. Immunother. 25 1 2002 72 81
23. T.F. Tedder Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19 J. Immunol. 141 12 1988 4388 4394
24. T.L. O'Keefe Mice carrying a CD20 gene disruption Immunogenetics 48 2 1998 125 132
25. L. Ginaldi Levels of expression of CD19 and CD20 in chronic B cell leukaemias J. Clin. Pathol. 51 5 1998 364 369
26. Q. Gong Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy J. Immunol. 174 2 2005 817 826
27. Y. Hamaguchi The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice J. Immunol. 174 7 2005 4389 4399
28. A.J. Grillo-Lopez Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma Semin. Oncol. 26 5 Suppl. 14 1999 66 73
29. A.J. Grillo-Lopez Rituximab: an insider's historical perspective Semin. Oncol. 27 6 Suppl. 12 2000 9 16
30. W.H. Wilson Chemotherapy sensitization by rituximab: experimental and clinical evidence Semin. Oncol. 27 6 Suppl. 12 2000 30 36
31. D.G. Maloney Mechanism of action of rituximab Anticancer Drugs 12 Suppl. 2 2001 S1 S4
32. T. Cerny Mechanism of action of rituximab Anticancer Drugs 13 Suppl. 2 2002 S3 S10
33. Y. Vugmeyster Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis J. Immunother. 28 3 2005 212 219
34. H. Tahir Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab Rheumatology (Oxford) 44 4 2005 561 562
35. N. Di Gaetano Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone Br. J. Haematol. 114 4 2001 800 809
36. S. Alas, and B. Bonavida Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs Cancer Res. 61 13 2001 5137 5144
37. D. Shan, J.A. Ledbetter, and O.W. Press Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells Cancer Immunol. Immunother. 48 12 2000 673 683
38. S. Alas, B. Bonavida, and C. Emmanouilides Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab Anticancer Res. 20 5A 2000 2961 2966
39. A. Harjunpaa, S. Junnikkala, and S. Meri Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms Scand. J. Immunol. 51 6 2000 634 641
40. J.K. Hofmeister, D. Cooney, and K.M. Coggeshall Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis Blood Cells Mol. Diseases 26 2 2000 133 143
41. S.P. Bohen Variation in gene expression patterns in follicular lymphoma and the response to rituximab Proc. Natl. Acad. Sci. U. S. A. 100 4 2003 1926 1930
42. S. Dall'Ozzo Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship Cancer Res. 64 13 2004 4664 4669
43. G. Cartron Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 3 2002 754 758
44. J.V. Ravetch, and S. Bolland IgG Fc receptors Annu. Rev. Immunol. 19 2001 275 290
45. W.K. Weng, and R. Levy Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Blood 98 5 2001 1352 1357
46. S.P. Treon Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies J. Immunother. 24 3 2001 263 271
47. J. Golay Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 95 12 2000 3900 3908
48. M.S. Cragg Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts Blood 101 3 2003 1045 1052
49. J.P. Deans, H. Li, and M.J. Polyak CD20-mediated apoptosis: signalling through lipid rafts Immunology 107 2 2002 176 182
50. C. Bezombes Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains Blood 104 4 2004 1166 1173
51. D. Shan, A.K. Gopal, and O.W. Press Synergistic effects of the fenretinide (4-hpr) and anti-cd20 monoclonal antibodies on apoptosis induction of malignant human b cells Clin. Cancer Res. 7 8 2001 2490 2495
52. P. McLaughlin Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma Semin. Oncol. 27 6 Suppl. 12 2000 37 41
53. P. McLaughlin, F.B. Hagemeister, and A.J. Grillo-Lopez Rituximab in indolent lymphoma: the single-agent pivotal trial Semin. Oncol. 26 5 Suppl. 14 1999 79 87
54. J.C. Edwards, M.J. Leandro, and G. Cambridge B lymphocyte depletion in rheumatoid arthritis: targeting of CD20 Curr. Dir. Autoimmun. 8 2005 175 192
55. B. Davies, T. Shaw, Rituximab pharmacokinetic characteristics are not influenced by combination with methotrexate or cyclophosphamide. Presented at EULAR, 2004.
56. J.C. Edwards, and G. Cambridge Prospects for B-cell-targeted therapy in autoimmune disease Rheumatology (Oxford) 44 2 2005 151 156
57. L.D. Piro Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Ann. Oncol. 10 6 1999 655 661
58. T. Maeda Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody Int. J. Hematol. 74 1 2001 70 75
59. R.J. Looney B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab Arthritis Rheum. 50 8 2004 2580 2589
60. J. Dunham A longitudinal analysis of SLE patients treated with rituximab: a comparison of B cell depleters to partial B cell depleters Arthritis Rheum. 52 9 Suppl. 2005 S740
61. J.H. Anolik The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus Arthritis Rheum. 48 2 2003 455 459
62. F. Zaja B-cell compartment as the selective target for the treatment of immune thrombocytopenias Haematologica 88 5 2003 538 546
63. T.J. Kipps Immune and cell therapy of hematologic malignancies Int. J. Hematol. 76 Suppl. 1 2002 269 273
64. I.P. Alwayn Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody Xenotransplantation 8 3 2001 157 171
65. V.K. Douglas Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma Am. J. Clin. Pathol. 112 6 1999 844 853
66. T.A. Davis Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab J. Clin. Oncol. 17 6 1999 1851 1857
67. C.M. Bearden Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174 Am. J. Transp. 5 1 2005 50 57
68. G.V. Gonzalez-Stawinski Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) Clin. Immunol. 98 2 2001 175 179
69. G. Cambridge Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis Arthritis Rheum. 48 8 2003 2146 2154
70. T.D. Levine, and A. Pestronk IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab Neurology 52 8 1999 1701 1704
71. K.A. Keogh Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum. 52 1 2005 262 268
72. P.E. Lipsky Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity Nat. Immunol. 2 9 2001 764 766
73. P.P. Sfikakis Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial Arthritis Rheum. 52 2 2005 501 513
74. S. Takemura T cell activation in rheumatoid synovium is B cell dependent J. Immunol. 167 8 2001 4710 4718
75. U. Winkler Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) Blood 94 7 1999 2217 2224
76. R.O. Dillman Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy Cancer Metastasis Rev. 18 4 1999 465 471
77. C.A. D'Arcy, and M. Mannik Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab) Arthritis Rheum. 44 7 2001 1717 1718
78. J.C.W. Edwards Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis Arthritis Rheum. 46 9 2002 S197 (abstract)
79. J.C. Edwards Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N. Engl. J. Med. 350 25 2004 2572 2581
80. M. Stewart Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab Ann. Rheum. Dis. 60 9 2001 892 893
81. M.J. Leandro, J.C. Edwards, and G. Cambridge Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Ann. Rheum. Dis. 61 10 2002 883 888
82. S. De Vita Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells Arthritis Rheum. 46 8 2002 2029 2033
83. C. Kelaidi Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (rituximab) monotherapy Leukemia 16 10 2002 2173 2174
84. M.N. Saleh A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia Semin. Oncol. 27 6 Suppl. 12 2000 99 103
85. N. Ahrens Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab) Br. J. Haematol. 114 1 2001 244 245
86. M.J. Leandro An open study of B lymphocyte depletion in systemic lupus erythematosus Arthritis Rheum. 46 10 2002 2673 2677
87. S.P. Treon CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia J. Immunother. 24 3 2001 272 279
88. T.D. Levine Rituximab in the treatment of dermatomyositis: an open-label pilot study Arthritis Rheum. 52 2 2005 601 607
89. Y. Cohen Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma Leuk. Lymphoma 42 6 2001 1405 1408
90. S. Berentsen Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease Br. J. Haematol. 115 1 2001 79 83
91. S. Perrotta Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus Br. J. Haematol. 116 2 2002 465 467
92. U. Specks Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy Arthritis Rheum. 44 12 2001 2836 2840
93. M. Zecca Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia Blood 97 12 2001 3995 3997
94. G. Remuzzi Rituximab for idiopathic membranous nephropathy Lancet 360 9337 2002 923 924
95. H.C. Hasselbalch B-cell depletion with rituximab-A targeted therapy for Graves' disease and autoimmune thyroiditis Immunol. Lett. 88 1 2003 85 86
96. S. Berentsen Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients Blood 103 8 2004 2925 2928
97. J.A. Gross TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Nature 404 6781 2000 995 999
98. J.H. Anolik Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus Arthritis Rheum. 50 11 2004 3580 3590
99. M. Odendahl Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus J. Immunol. 165 10 2000 5970 5979
100. M. Mihara CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus J. Clin. Invest. 106 1 2000 91 101
101. L. Schiffer Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition J. Immunol. 171 1 2003 489 497